|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms with t(8;22)(p11.2;q11.2)/BCR-FGFR1: a meta-analysis of 20 cases shows cytogenetic progression with B-lymphoid blast phase.
|
28551329 |
2017 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).
|
10688839 |
2000 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
FGFR1 translocation with concurrent myeloproliferative neoplasm, systemic mastocytosis, and lymphoblastic lymphoma: a case report.
|
29107667 |
2018 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13).
|
9576949 |
1998 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
A ZMYM2-FGFR1 8p11 myeloproliferative neoplasm with a novel nonsense RUNX1 mutation and tumor lysis upon imatinib treatment.
|
23751892 |
2013 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-type FGFR kinases, whereas FGFR1-TACC1, FGFR2-AFF3, FGFR2-BICC1, FGFR2-PPHLN1, FGFR3-BAIAP2L1 and FGFR3-TACC3 fusions in solid tumors are transmembrane-type FGFRs with C-terminal alterations.
|
27245147 |
2016 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
By analogy with these, we propose that the RAMP-FGFR1 fusion product will contribute to progression of this myeloproliferative disorder by constitutive activation of tyrosine kinase function.
|
9499416 |
1998 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation.
|
10480903 |
1999 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder.
|
17321332 |
2007 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature.
|
18096225 |
2008 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease.
|
21527531 |
2011 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
CTD_human |
Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.
|
21936542 |
2011 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Dual lympho-myeloproliferative disorder in a patient with t(8;22) with BCR-FGFR1 gene fusion.
|
15870860 |
2005 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3).
|
12393597 |
2003 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Finally, translocations associated with the rare 8p11 myeloproliferative syndrome and other atypical myeloproliferative disorders have permitted the identification of a number of novel fusion proteins involving fibroblast growth factor receptor-1.
|
11640868 |
2001 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Fine-needle aspiration cytology of T-lymphoblastic lymphoma associated FGFR1 rearrangement myeloproliferative neoplasm.
|
23904402 |
2014 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice.
|
12969958 |
2004 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Further FISH indicated a breakpoint within fibroblast growth factor receptor 1 (FGFR1), the receptor tyrosine kinase that is known to be disrupted in a distinctive myeloproliferative disorder, most commonly by fusion to ZNF198.
|
11739186 |
2001 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
|
11746971 |
2001 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
LHGDN |
Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.
|
11746971 |
2001 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Hematologic malignancies associated with FGFR1 abnormalities present in heterogeneous forms, including myeloproliferative neoplasm, acute myeloid leukemia (AML), T- or B-lineage lymphoblastic leukemia/lymphoma, and even mixed phenotype acute leukemia.
|
23609419 |
2013 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here we describe another case of myeloproliferative neoplasm with chromosome translocation t(8;19) involving FGFR1 gene associated with systemic mastocytosis.
|
24551307 |
2014 |
|
Myeloproliferative disease
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Here, we report a new translocation at the FGFR1 locus in a patient who carried t(1;8)(q25;p11.2) and presented with myeloproliferative neoplasm-like symptoms.
|
22619110 |
2012 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Important changes include (1) the change of nomenclature of myeloproliferative disorder to myeloproliferative neoplasm emphasizing the clonal nature of these disorders; (2) the classification of mast cell disease as an MPN; (3) the reorganization of the eosinophilic disorders into a molecularly defined category of PDGFRA, PDGFRB and FGFR1-associated myeloid and lymphoid neoplasms with eosinophilia and chronic eosinophilic leukemia, not otherwise specified; and (4) refinement of the diagnostic criteria for PV, ET and PMF incorporating recently described molecular markers, JAK2V617F, JAK2 exon 12 mutations and MPL mutations.
|
20191332 |
2010 |
|
Myeloproliferative disease
|
0.400 |
Biomarker
|
group |
BEFREE |
Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.
|
16410451 |
2006 |